B
17.29
-0.12 (-0.69%)
| Penutupan Terdahulu | 17.41 |
| Buka | 17.20 |
| Jumlah Dagangan | 133,349 |
| Purata Dagangan (3B) | 348,838 |
| Modal Pasaran | 940,845,760 |
| Harga / Buku (P/B) | 1.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| EPS Cair (TTM) | -1.09 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.09% |
| Nisbah Semasa (MRQ) | 36.01 |
| Aliran Tunai Operasi (OCF TTM) | -52.76 M |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Bicara Therapeutics Inc. | - | - |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.26% |
| % Dimiliki oleh Institusi | 67.15% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 47.00 (Stifel, 171.83%) | Beli |
| Median | 42.00 (142.92%) | |
| Rendah | 35.00 (Morgan Stanley, 102.43%) | Beli |
| Purata | 41.33 (139.04%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 22.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Dec 2024 | 42.00 (142.91%) | Beli | 21.10 |
| Morgan Stanley | 08 Oct 2024 | 35.00 (102.43%) | Beli | 22.55 |
| Stifel | 08 Oct 2024 | 47.00 (171.83%) | Beli | 22.55 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |